Sangui BioTech International Inc.
Sangui BioTech International Inc.: Sales of USD 9,711 in the first three months; Costs and loss halved.
DGAP-News: Sangui BioTech International Inc. / Key word(s): Quarter Results
Sangui BioTech: – Sales of USD 9,711 in the first three months;
The cost – cutting – and liability – protection program adopted during the last year shows first success. Thus, the cost of business operations for the quarter could be reduced by USD 93,490 or 54% to USD 79,322. As a result of this, the operating loss of the quarter decreased compared to the prior year quarter by USD 91,533 to USD 69,893. Accordingly, the cash position of the Company during the reporting period improved. After declining royalty income due to lower turnover of the wound treatment product Granulox in previous quarters, the company expects for the further development of the fiscal year 2017 rising sales of Granulox and accordingly increasing royalty income. This forecast is based on the successful integration of new sales partners (UK and Southeast Asia) as well as positive developments in already developed sales areas. Sangui BioTech International, Inc. (“SGBI”) is a holding company the shares of which are being traded on the OTCQB venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are current in their reporting and undergo an annual verification and management certification process. Sangui shares also trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc. For more information please contact: Some of the statements contained in this news release discuss future expectations, contain projections of results of operation or financial condition or state other “forward-looking” information. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. Important factors that may cause actual results to differ from projections include, among many others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
2016-11-23 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |